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Borrelia burgdorferi is a spirochetal bacterium that causes Lyme disease. These studies address whether current research methods
using either ELISA to detect seroconversion to B. burgdorferi antigens or PCR quantiﬁcation of bacterial DNA within tissues
can accurately distinguish between a productive infection versus a B. burgdorferi exposure that is rapidly cleared by the innate
responses. Mice receiving even minimal doses of live B. burgdorferi produced signiﬁcantly more B. burgdorferi-speciﬁc IgM and
IgG than groups receiving large inocula of heat-killed bacteria. Additionally, sera from mice injected with varied doses of killed B.
burgdorferi recognized unique borrelial antigens compared to mice infected with live B. burgdorferi. Intradermal injection of killed
B. burgdorferi resulted in rapid DNA clearance from skin, whereas DNA was consistently detected in skin inoculated with viable
B. burgdorferi. These data indicate that both ELISA-based serological analyses and PCR-based methods of assessing B. burgdorferi
infection clearly distinguish between an established infection with live bacteria and exposure to large numbers of bacteria that are
promptly cleared by the innate responses.
1.Introduction
Borrelia burgdorferi (Bb) is a spirochetal bacterium that
causes Lyme disease [1]. Introducing this pathogen into the
skin of susceptible hosts, either via the bite of an infected
tick or by injection of culture-grown bacteria, leads to their
subsequent dissemination to several tissues, including heart,
joint, and neural tissues [2]. These spirochetes are notable in
their ability to persist for months to years within host tissues,
with intermittent reemergence promoting the acute localized
inﬂammatory lesions that characterize Lyme disease. While
these persistent bacteria elicit strong innate and adaptive
immune responses, their fastidious growth requirements
have hindered in vitro analyses to determine which elements
of host immunity are most important for controlling these
infections [3–7].
Most studies to assess immune responses against B.
burgdorferi are performed using a well-described murine
model of Lyme disease. Mice are a natural reservoir for
B. burgdorferi, and persistent bacteria within certain inbred
strains are associated with similar tissues and produce
inﬂammatory pathology consistent with that exhibited in
human patients, though the severity of disease can vary
widely between diﬀerent inbred mouse strains [8–10]. Infec-
tion studies using inbred strains have allowed identiﬁcation
of speciﬁc immune mediators that aﬀect host clearance, such
as Toll-like receptor 2 (TLR2) [11, 12], MyD88 [13, 14],
CD14 [15, 16], IL-10 [17, 18], the chemokine KC [19], and
the production of antibodies against critical B. burgdorferi
antigens [20–24].
Studies elucidating the basis of B. burgdorferi clearance
have relied heavily on two parameters, namely, seroconver-
sion to bacterial antigens and detection of bacterial DNA in
host tissues. Production of high antibody titers against cer-
tain B. burgdorferi antigens, which have been further charac-
terized using western blot analyses, can protect animals from
both tick-mediated and syringe challenge with B. burgdorferi
[9, 22, 25]. The speciﬁc eﬀects of antibodies and other
immune mediators on B. burgdorferi clearance have tradi-
tionally been measured qualitatively by culturing murine2 Clinical and Developmental Immunology
tissues in sterile BSK medium and determining whether
resident spirochetes can grow from these cultures [26]. More
recently, real-time PCR techniques have been developed that
can accurately quantify even minute B. burgdorferi levels
in murine target tissues [17, 27, 28], and similar methods
have been used to compare the upregulation of targeted
murine and bacterial gene products within infected tissues
[18, 29, 30]. The reﬁnement of these techniques have greatly
improved the usefulness of the murine model of Lyme
disease, particularly in identifying immune mediators that
are eﬀective in controlling these unique pathogens.
While both ELISA techniques, to measure antibody
levels, and PCR analyses, to determine B. burgdorferi levels,
are widely used to assess the development of Lyme disease
in infected animals, questions have been raised regarding
how accurately these techniques assess the infection status.
B. burgdorferi are known to be highly immunogenic, largely
due to the wide range of lipoproteins that are produced
in response to diﬀerent environmental cues [6, 31, 32].
These lipoproteins all possess a triacyl modiﬁcation on their
amino terminus [33] that not only activates many diﬀerent
host immune cells through interaction with TLR2 [11, 34–
36] but also provides potent adjuvant activity that signif-
icantly enhances antibody responses to these lipoproteins
[37, 38]. This raises the possibility that mice receiving a
signiﬁcantinoculummayproducesubstantial B.burgdorferi-
speciﬁc antibodies that do not truly reﬂect a response to
an active infection, but alternatively reﬂect an antibody
response to an initial inoculum that was quickly cleared;
in these cases, diﬀerences between active and subclinical
infection would only be apparent by subsequent western blot
analyses. A second issue is that B. burgdorferi can persist
in many diﬀerent tissues, but the precise extracellular or
intracellular microenvironment in which they persist, as
well as the immunoprivileged status of that niche, is still
being deﬁned [39–42]. It is plausible that bacterial products
from killed bacteria, such as DNA, might escape timely or
complete clearance from those tissues, and, thus, subsequent
assessment could falsely indicate that viable B. burgdorferi
were persisting in those tissues. To address these issues, we
have injected mice with various doses of live and heat-killed
bacteria to determine whether signiﬁcant and characteristic
diﬀerences in both antibody production, as assessed by
ELISA analyses, and detection of B. burgdorferi DNA, by
PCR, can accurately reﬂect whether the mice were actively
infected or were only exposed to a threshold level of bacterial
antigens.
2.MaterialsandMethods
2.1. Infection of Mice with Borrelia burgdorferi. C57BL/6NCr
(B6) mice were obtained from the National Cancer Institute:
Frederick Animal Production Program (Frederick, MD).
Mice were housed in the Department of Lab Animal
Resources at the University of Toledo Health Sciences Cam-
pus according to the National Institutes of Health guidelines
for the care and use of laboratory animals. All protocols were
reviewed and approved by the Institutional Animal Care and
Usage Committee.
T h ec l o n a lN 4 0i s o l a t e[ 43]o fB. burgdorferi was gener-
ously provided by Steve Barthold (University of California,
Davis) as a passage two culture after isolation from the uri-
nary bladder of a Rag-1−/− mouse. For all infections, a pas-
sage 4 culture was grown in BSK-II medium supplemented
with 6% rabbit serum (Sigma Chemical, St. Louis, Mo, USA)
for3–5 days at 33◦C anddirectlyenumeratedusinga Petroﬀ-
Hauser’s chamber and dark ﬁeld microscopy. B6 na¨ ıve mice
were infected with the indicated numbers of viable or heat-
killed B. burgdorferi in a 20µL volume by intradermal
injection into a shaven back. These bacteria remain intact
afterheatkilling(55◦Cfor1hour)basedonvisualinspection
and counting by dark ﬁeld microscopy but are subsequently
unable to grow in BSK medium (data not shown).
2.2. Immunoglobulin (Ig) Quantiﬁcation. Serum was ob-
tained at the indicated times by either retroorbital bleeding
or exsanguination, and Ig content was assessed using pre-
viously described ELISA techniques [17]. Brieﬂy, microtiter
plateswerecoatedwitheithersonicatedB.burgdorferiorgoat
antibodies to mouse IgG, IgM, and IgA (Southern Biotech,
Birmingham, Ala, USA). Multiple serum dilutions were
a d d e dt op l a t e sf o r9 0 m i na t3 7 ◦C, and bound murine Ig
was detected by addition of isotype-speciﬁc HRP-conjugated
antibodies (Southern Biotech). Ig content was quantiﬁed by
comparison to standard curves constructed by using puriﬁed
Ig of the appropriate isotype (Southern Biotech).
2.3. Western Blot Analysis. One hundred twenty µg of soni-
cated cN40 isolate were electrophoresed in a 4–12% Bis-Tris
gel (Invitrogen) containing a single large well, transferred to
Immobilon-P membrane (Millipore, Bedford, Mass, USA),
and immunoblotted using a Surf Blot apparatus (Idea Scien-
tiﬁcCompany,Minneapolis,Minn,USA).Immuneseraused
to blot the membrane were obtained from B6 mice at day
28 after inoculation with viable or heat-killed B. burgdorferi.
Antibody-antigen complexes were detected by addition of
HRP-conjugated antibodies speciﬁc for total murine Ig
(Southern Biotech) and visualized by chemiluminescence.
Multiple ﬁlm exposure times were acquired for each blot to
ensure that all protein bands were recorded irrespective of
concentration variances between samples.
2.4. DNA Preparation. Murine skin tissues encompassing
(6mm diameter) the Bb injection site were harvested
from experimental animals sacriﬁced at the indicated times
after injection, and DNA was prepared from individual
tissues as previously described [10]. Brieﬂy, tissue specimens
were incubated in 0.1% collagenase A (Roche Diagnostics,
Indianapolis, Ind, USA) at 37◦C overnight, followed by the
addition of an equal volume of 0.2mg/mL proteinase K
(Invitrogen, Carlsbad, Calif, USA) and incubation overnight
at 55◦C. DNA was recovered by multiple phenol-chloroform
extractions and ethanol precipitation and includes diges-
tion of contaminating RNA in 1mg/mL DNase-free RNase
(Sigma), with the ﬁnal sample resuspended in 500µLo fT E
buﬀer. The DNA content was quantiﬁed by absorbance at
260nm, and working samples were diluted to 50µg/mL for
quantitative real-time PCR analyses.Clinical and Developmental Immunology 3
2.5. Quantiﬁcation of B. burgdorferi in Mouse Tissues. The
number of spirochetes resident in the diﬀerent murine target
tissuesweredeterminedviaPCRanalysesusingaLightCycler
(Roche Diagnostics) rapid ﬂuorescence temperature cycler
based on our previously described protocols [17, 28]. Brieﬂy,
ampliﬁcation was performed on 100ng of template DNA
in a 10µL ﬁnal volume containing 50mM Tris (pH 8.3),
3mM MgCl 2,4 . 5 µg of bovine serum albumin, 200µM
of each deoxynucleoside triphosphate, a 1:10,000 dilution of
SYBR Green I (Molecular Probes, Eugene, Ore, USA),
1µM of each primer (Integrated DNA Technologies, Cor-
alville, Iowa, USA), and 0.5U of Platinum Taq DNA Polym-
erase(Invitrogen).Copy numbersforthemouse nidogen and
B. burgdorferi recAg e n e sp r e s e n ti ne a c hs a m p l ew e r ec a l -
culated by extrapolation to standard curves using Light-
Cycler software (Roche Diagnostics). The reported data
represents recA values that were corrected by normalization
based on the nidogen (nid)g e n ec o p yn u m b e r .T h eo l i g o -
nucleotideprimersusedtodetectmousenidogenwerenido.F
(5 -CCA GCC ACA GAA TAC CAT CC-3 ) and nido.R (5 -
GGA CAT ACT CTG CTG CCA TC-3 ). The oligonucleotide
primers used to detect B. burgdorferi recA were nTM17.F
(5 -GTC GAT CTA TTG TAT TAG ATG AGG CTC TCG-3 )
and nTM17.R (5 -GCC AAA GTT CTG CAA CAT TAA CAC
CTA AAG-3 ).
2.6. Statistical Analyses. The statistical signiﬁcance of the
quantitative diﬀerences between the diﬀerent sample groups
was determined by application of Student’s two-tailed t-test;
P values that were ≤0.05 were considered signiﬁcant.
3. Results
3.1. Quantiﬁcation of Bb-Speciﬁc Ig Levels in Serum. We
initially wanted to determine whether distinct quantitative
diﬀerences are detectable in antibody levels produced during
an active Bb infection versus bacterial exposures that are
quickly resolved. To address this, groups of B6 mice were
injected with diﬀerent doses of live or heat-killed bacteria,
and the Bb-speciﬁc Ig content of individual sera collected
either 2 or 4 weeks after infection was compared by ELISA
analysis. Sera from control mice that were injected only
with BSK II medium contained no Bb-speciﬁc IgG and
minimal levels of Bb-speciﬁc IgM (Figure 1), which reﬂects
the presence of natural Bb-speciﬁc IgM in na¨ ıve mice, as
previously reported [44, 45]. Mice injected with live bacteria
showedhigherBb-speciﬁcIgMlevelsat2weeks(Figure1(a))
than at 4 weeks (data not shown), and while low levels of
Bb-speciﬁc IgG were seen at 2 weeks after infection (data
not shown), the levels were much higher at 4 weeks post-
infection (Figures 1(a) and 1(b)). Injecting a single dose of
heat-killed Bb into B6 mice, with or without CFA, did not
elicit signiﬁcantly enhanced IgM levels compared to mice
receiving BSK II medium alone (Figure 1(a)), even at a dose
of 5 × 107 killed Bb. However, injection of as few as 250 live
bacteria increased the Bb-speciﬁc IgM levels by over 200-
fold compared to mice receiving the highest dose of killed
bacteria (P ≤ 1.6 × 10
−5) by 2 weeks post-infection. A
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Figure 1: Comparison of Bb-speciﬁc antibody levels produced
during active infection versus exposure to high numbers of killed
bacteria. (a) Groups of B6 mice were injected with a single dose
of live or heat-killed Bb, and serum was collected at either 2 or 4
weeksafterinfection;insomecasesthekilledBbinoculumincluded
an equal volume of complete Freund’s adjuvant (CFA). The doses
injected ranged from 1000 (“1e3”) to 5 × 107 (“5e7”) killed bacteria,
and 250 to 5 × 104 (“5e4”) live Bb. Individual sera were assessed
for Bb-speciﬁc IgM content at 2 weeks after infection and for
IgG content at 4 weeks after infection by ELISA analyses. Each
circle represents the serum value for an individual animal, and the
number beside the bar indicates the average value for that group.
∗indicates values that are signiﬁcantly diﬀerent from control mice
(Un); ∗∗indicates values that are signiﬁcantly diﬀerent from mice
injected with killed bacteria. (b) The sera assessed for IgG content
in (a) were also assessed for the levels of the indicated individual
IgG isotypes using similar ELISA techniques.4 Clinical and Developmental Immunology
somewhat similar trend was seen in IgG levels at 4 weeks
post-infection,whereadoseof5 ×106 killedBbwasrequired
to signiﬁcantly increase Bb-speciﬁc IgG levels compared to
na¨ ıve mice (P = 0.011). Again, injection with as few as 250
live bacteria increased the Bb-speciﬁc IgG levels by over 20-
fold compared to mice receiving the highest dose of killed
bacteria (P ≤ 2.3 × 10
−6) by 4 weeks post-infection. These
data indicate that signiﬁcant quantitative diﬀerences in Bb-
speciﬁc antibodies are readily detected in sera from animals
that sustain an active infection compared to those exposed to
relatively high numbers of killed Bb that are quickly cleared.
To determine whether these diﬀerences in IgG produc-
tionextendedtoallIgGisotypes,similarELISAanalyseswere
performed and developed using isotype-speciﬁc detection
antibodies (Figure 1(b)). The production of IgG2b and IgG3
isotypes showed a similar trend as reported for Bb-speciﬁc
IgG, in that signiﬁcant levels of Bb-speciﬁc antibodies were
only observed at the very highest dose of killed bacteria,
while administration of as few as 250 live Bb resulted in ≥10-
fold increase in Bb-speciﬁc antibodies (P = 0.001 and 0.01,
resp.). In contrast, IgG1 production appeared much more
responsive to killed bacteria, with signiﬁcant increases in Bb-
speciﬁc IgG1 elicited in response to 5 × 106 killed bacteria,
andtheselevelsweresimilartothoseproducedinresponseto
alllivebacteriainocula,exceptforthehighestdose.However,
the overall quantities of IgG1 antibodies were ≥200-fold less
than the other isotypes assessed, and thus represent a minor
component of the total IgG response.
3.2. Comparison of Bb Antigens Recognized by Antisera to Live
and Killed Bb. Bb can rapidly modulate a large number of
surface-exposed and other lipoproteins during their natural
infection cycle from arthropod to vertebrate host [31, 32,
46–48]. Therefore, it is likely that the antigens that are
immunologically recognized during an active infection diﬀer
from those in a killed Bb exposure that is rapidly cleared, and
could be used to further conﬁrm the signiﬁcant diﬀerences
in antibody production observed in the ELISA analyses. To
address this, sera were collected from mice injected with
various doses of live and killed Bb at 4 weeks post-infection,
andusedforwesternblotanalysestocomparetherangeofBb
antigens that are recognized by each serum (Figure 2). Mice
injected only with BSK II medium (lanes 2-3) possessed no
detectable Bb-reactive antibodies, while a mAb speciﬁc for
Bb OspA (lane 1) appeared to detect both the monomeric
and dimeric forms of this lipoprotein. As expected based
on the ELISA analyses (Figure 1), an approximately 20-fold
higher concentration of serum from animals injected with
killed bacteria was needed to eﬀectively visualize Bb antigens
compared to sera generated against live bacteria (Figure 2).
Sera from mice that received either a single (lanes 7–9) or
boosted dose (lane 13) of killed Bb demonstrated a protein
recognition pattern that was distinct from mice receiving
either a low (lanes 10–12) or high (lanes 14–16) dose of
live Bb. These studies indicate that signiﬁcant quantitative
and qualitative diﬀerences are apparent in the antibodies
producedbetweenmicethatundergoanactiveinfectionwith
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Figure 2: Antibodies produced against live and killed spirochetes
recognize unique Bb antigens. Sera were collected from individual
mice 4 weeks after injection with a single dose of either BSK II
medium (lanes 2-3), 5 × 107 killed Bb (lanes 4–9), 250 live Bb
(lanes 10–12), or 5 × 104 live Bb (lanes 14–16); one group initially
received 105 killed Bb + CFA, with a boost 3 weeks later with 105
killed Bb + IFA, and sera collected 3 weeks later (lane 13). All sera
were diluted either 1:25 (lanes 2-3 and 7–9) or 1:500 before using
to immunoblot membranes containing electrophoresed Bb. A mAb
speciﬁc for Bb OspA, H5332 [49], was included as a marker for
OspA reactivity (lane 1).
Bb and those which rapidly clear a relative large bacterial
inoculum.
3.3. Persistence of Bb DNA in Skin Tissues. PCR-based assays
arecommonlyusedtoquantifydiﬀerencesinBblevelswithin
host tissues for a number of model systems; however, it is not
clear how long the DNA from killed bacteria might persist in
those tissues and provide inaccurate estimation of the viable
Bb numbers. To address this, parallel groups of mice were
injected intradermally with either live or killed Bb, and skin
tissues were harvested and assessed at diﬀerent times after
injection for the presence of bacterial DNA by real-time PCR
using our described protocols [17, 28]. Skin tissues harvested
immediately after injection of equal numbers of live or killed
Bb showed the presence of similar numbers of Bb genomes
by PCR analyses (Figure 3), and, by 8h after injection, these
numbers have substantially decreased to similar low levels in
animals receiving both live and killed bacteria. After 8h after
injection,almostnoBbgenomesweredetectedinskintissues
of animals receiving killed bacteria (Figure 3), and more
extensive studies showed that no Bb genomes were detected
in skin, ear, ankle, or heart tissues of mice receiving killedClinical and Developmental Immunology 5
bacteria at 2 and 4 weeks after injection (data not shown).
Alternatively, mice receiving live bacteria showed a gradual
increase in skin Bb levels after 8h following infection, with
the highest bacterial numbers detected at 96h after infection
(Figure 3), and reduced but consistent levels noted at 2 and
4 weeks after injection (data not shown). These ﬁndings
suggest that killed Bb are rapidly cleared from skin tissues
and that their genome content can no longer be detected by
PCR within hours of being killed.
4. Discussion
The spirochetal pathogen B. burgdorferi (Bb) is an obli-
gate parasite that cycles eﬃciently between vertebrate and
arthropod hosts and persists for extended periods within
various host tissues. Antigenic variation has been described
to play a putative role in immune evasion, but other
mechanisms by which these bacteria evade clearance from
immunocompetent hosts are not well deﬁned. The fastidious
growth requirements of these spirochetes make it diﬃcult
to design stringent in vitro analyses that accurately reﬂect
host conditions. Therefore, infection studies using inbred
mouse lines are the gold standard for addressing host-Bb
interactions. Both ELISA and western blot analyses have
been useful in measuring the critical antibody responses to
Bb infection, including the identiﬁcation of immunoreactive
bacterial products that can confer protective immunity and
in determining infection rates by seroconversion. Similarly,
the recent development of quantitative real-time PCR tech-
niques has allowed researchers to distinguish important
diﬀerences in immune clearance between diﬀerent murine
model strains and, thus, identify mechanisms that are critical
for clearance of these persistent bacteria. The sensitivity and
speciﬁcity of these assays are well documented, but questions
have arisen as to their abilities to diﬀerentiate between
active infections versus those produced by residual and/or
stimulatory bacterial products that persist subsequent to
bacterial killing. Our study attempts to clarify the limitations
of these techniques in assessing the murine infection model
of Lyme disease.
B. burgdorferi is notable in that ≥8% of putative protein-
coding genes contain a signal peptide “lipobox” region,
suggesting that these gene products are recognized by lipid
modiﬁcation enzymes that produce triacylated lipoproteins
[6, 7, 33]. These lipoproteins can be secreted across the cyto-
plasmic membrane to the outer membrane [50], where they
are not only recognized by the adaptive immune responses
but can also interact with TLR2 on a number of diﬀerent
immune cell types to induce inﬂammatory responses [11].
As a result of these interactions, Bb lipoproteins are highly
immunogenic and possess endogenous adjuvant activities
that make them attractive vaccine candidates [38, 51, 52],
suchastheOspA-basedLYMErixvaccine[53].Infectionwith
as few as 20 organisms can lead to the production of high
levelsofBb-speciﬁcantibodiesby2to4weeksafterinfection,
which corresponds with a subsequent decrease of bacterial
numbers in host tissues, suggesting the importance of these
antibodies in controlling bacterial numbers [22, 54, 55].
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Figure 3: DNA from killed Bb is rapidly cleared from infection
sites and is undetectable by PCR. Groups of mice were injected
intradermally with 104 of either live or heat-killed Bb. Mice were
sacriﬁced at the indicated times after injection, and a 6mm skin
sample encompassing the injection site was excised for DNA
preparation. The relative Bb levels were assessed by real-time PCR
using recA primers and normalized relative to the murine nid
content. Each circle represents Bb recA levels relative to 1000nid
copies for an individual animal, and the number beside the bar
indicates the average value for that group. These data reﬂect the
combined results of two separate experiments.
While increases in Bb-speciﬁc antibody levels are often
used as an indicator of infection, it is possible that this
correlation is misleading, since even a Bb inoculum that is
rapidly cleared by the innate immune responses would result
in the presentation of a substantial number of immunogenic
lipoproteins to T and B cells, which could potentially elicit
antibody levels that approach those produced by infected
animals.However,wefoundthatmiceinjectedintradermally
with a single dose of either live or heat-killed Bb produced
sera with distinct diﬀerences. A dose of at least 5 × 106
killed bacteria was required to elicit detectable Bb-speciﬁc
antibodies, but even 5 × 107 killed bacteria elicited 20- to
400-foldlessBb-speciﬁcantibodylevelsthananytesteddoses
of live bacteria. These large diﬀerences were noted in all Ig
isotypes tested except for IgG1 production. Overall, these
data suggest that signiﬁcant diﬀerences are apparent between
the antibody levels produced in response to a productive Bb
infection versus exposure to killed bacteria and that properly
controlled ELISA analyses can reliably distinguish the two.
During their natural infection cycle, Bb must quickly
adapt to a wide range of arthropod and vertebrate envi-
ronments in order to survive. Many of these changes are
associated with rapid expression changes involving multiple
surface lipoproteins [56]. For example, OspA is highly
expressed on the surface of Bb within the tick midgut or
when cultured in BSK medium at ambient temperatures
[47]. However, the process of tick feeding or increases
in temperature cause the rapid downregulation of OspA
and subsequent upregulation of numerous lipoproteins
associatedwithmammalianinfection,suchasOspC[46,57],
the Erp family proteins [30], and diﬀerent modiﬁcations
of the vlsE-expressed lipoprotein [58]. Thus, Bb introduced
into a murine host will diﬀerentially express a large number
of diﬀerent lipoproteins during the course of infection
and should subsequently present a much broader range of
antigens to host immune cells than Bb that are rapidly killed.6 Clinical and Developmental Immunology
Our studies determined that the Bb proteins recognized by
sera from mice injected with killed Bb were distinct from the
proteins recognized by sera from mice injected with live Bb.
Based on size and the OspA control, the response to killed
Bbappearedlargelydirectedagainstproteinbandsconsistent
with OspA monomers (∼31kDa) and dimers (∼62kDa),
while the response to live Bb appeared directed to proteins
with band sizes consistent with p39 (∼39kDa), ﬂagellin
(∼41kDa), and p93 (∼93kDa); these diﬀerent reactivities
to proteins recognized on live Bb have been previously
noted by diﬀerent investigators [8, 46, 59–61]. Because
these changes in antigen expression have been shown to
correspond with active infection, our western blot data
conﬁrms that the signiﬁcant diﬀerences in ELISA values can
accurately distinguish between animals that experienced a
progressive Bb infection versus an exposure to bacteria that
could not adapt to escape host clearance.
Subsequent to inoculation in a murine host, Bb are
known to disseminate from the skin and persist in a wide
range of tissues (including the skin). While the precise
environmentthatthesebacteriaprefertopersistwithinisnot
well deﬁned, they are believed to largely exist extracellularly.
Bb can associate with collagen bundles [62, 63], decorin-
associated tissues [41, 64], or relatively avascular spaces
throughout their host [65], all of which might provide
some protection from immune recognition/clearance. Alter-
natively, Bb might be able to persist within some immune
cells subsequent to phagocytosis, with both live and killed
bacteria appearing to remain intact for extended periods of
time [66]. These possibilities suggest that even Bb that are
killed within host tissues might persist for extended times
and, thus, could allow their cellular contents to be detected
by assays designed to detect viable persistent bacteria, such
as PCR of infected tissues. We addressed this by injecting
mice with live and killed Bb and following the Bb content in
the skin over time by PCR analysis. Levels of PCR-detectable
bacteria declined to similar low levels by 8h after injection
in both groups, likely due to both the degradation of DNA
content from killed Bb, as well as the dissemination of live
Bb away from the harvested skin injection site. However, the
BbDNAcontentintissuesreceivinglivebacteriaincreasedto
r eachpeakvaluesb y96handsubsequentlyr emainedlo wbut
signiﬁcant.Thispatternisconsistentwithpreviousreportsof
Bbpersistencewithinskintissues[8,12].Ourcurrentstudies
suggest that killed Bb and their cellular content are eﬃciently
cleared in skin tissues and should not be detectable by PCR
methodologies within hours of being killed. In summary,
both serological and PCR-based methods of assessing Bb
infection clearly distinguish between an established infection
with live bacteria and exposure to even large numbers of
bacteria that are cleared early by the innate responses.
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